Opens in a new tab

Amgen v Sanofi-Aventis Deutschland (CFI, 24 August 2023)

Date24 August 2023
CourtCFI
DivisionMunich (DE) Central Division - Section
Type of actionPreliminary objection
Case number(s)UPC_CFI_1/2023
Registry referenceORD_560432/2023 · UPC_CFI_1/2023
PartiesAmgen, Inc. v. Sanofi-Aventis Deutschland GmbH

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 24 August 2023 (UPC_CFI_1/2023, ACT_459505/2023), the judge-rapporteur of the Munich section of the Central Division rejected Amgen’s preliminary objection to Sanofi’s revocation action against EP 3 666 797. On 1 June 2023, with the CMS out of service, Sanofi had lodged its Statement for revocation in hard copy at the Luxembourg Registry at 11.26, and Amgen its infringement action at the Munich Local Division sub-registry at 11.45. The order, which grants leave to appeal of the Court’s own motion, settles to the minute the priority required by Art. 33(4) UPCA.

Question

Does the Central Division remain competent where an infringement action between the same parties on the same patent is brought before a local division on the same day, a few minutes after the revocation action?

Decision

« Bringing an action » means the objective act of lodging the statement, the requirements of Rule 13 RoP not being a precondition, since Art. 33(4) UPCA lays down no further requirement (paragraphs 4.22 and 4.23), any arbitrary assignment after an action is brought must be ruled out (paragraph 4.19). Priority is determined by the exact date and time of lodging (paragraph 4.26). Rule 4.2 RoP offers a choice between the Registry, at the seat of the Court of Appeal in Luxembourg, and a sub-registry, Amgen’s narrower reading being rejected (paragraphs 4.39 to 4.43), the Registry Rules cannot override the Rules of Procedure (paragraphs 4.49 to 4.51). The outcome is fair, as a party should not be disadvantaged merely by its geographical location (paragraph 4.52). As no infringement action was pending at 11.26, the Central Division is competent (paragraph 4.53). The costs request was rejected (paragraph 4.55).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 10, 32(1), 33(2) to (4), 73(2)(b)(ii) and 83(3), Statute, Arts. 23, 24 and 25
Rules of Procedure
Rules 4.1, 4.2, 13, 16, 17, 19.1(b), 20.2, 21.1, 49, 220.2 and 224.1(b)
Regulation 1215/2012
Arts. 24(4), 31, 71a and 71b

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Local and central divisions (UPC).

Dhenne Avocats blog: The Transitional Period and the UPC: Coordinating Two Judicial Orders.

Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, Valeo v. Bosch and the Redistribution of Cases Within the UPC (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_1/2023 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 29 June 2023 Sanofi-Aventis Deutschland v Amgen (CFI, 29 June 2023) Revocation Action · UPC_CFI_1/2023

    Les documents déposés par les sociétés Sanofi sont admis comme pièces de la demande en nullité, réputée signifiée à Amgen le 29 juin 2023.

  2. 24 August 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 24 August 2023) Preliminary objection · UPC_CFI_1/2023
  3. 20 September 2023 Sanofi-Aventis Deutschland v Amgen (CFI, 20 September 2023) Revocation Action · UPC_CFI_1/2023

    Le juge rapporteur rejette la demande d'accès aux écritures et pièces d'un mandataire souhaitant se forger une opinion sur la validité du brevet, faute de motif concret et vérifiable, et autorise l'appel.

  4. 24 January 2024 Sanofi-Aventis Deutschland v Amgen (CFI, 24 January 2024) Revocation Action · UPC_CFI_1/2023

    Le juge rapporteur admet la lettre des demanderesses et ses déclarations d'experts répondant à des points nouveaux de la duplique, et rejette les demandes d'Amgen tendant à la clôture immédiate ou à une réplique supplémentaire.

  5. 24 February 2024 Sanofi v Amgen (CFI, 24 February 2024) Revocation Action · UPC_CFI_1/2023

    L'action en nullité de Sanofi et la demande reconventionnelle en nullité de Regeneron contre le brevet d'Amgen sont instruites conjointement en vue d'une audience le 4 juin 2024, la valeur de chaque action étant fixée à 100 millions d'euros.

What the record states

Nature of the act
Preliminary objection
Outcome (Dhenne Avocats summary)
L'action en nullité déposée au greffe de Luxembourg à 11 h 26 précède l'action en contrefaçon déposée à 11 h 45, la division centrale est compétente et l'exception préliminaire est rejetée.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 666 797
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
recorded proprietor: Amgen Inc
Mentioned in the analysis (role not qualified)
Also mentioned in 21 other decision(s): Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) · Sanofi-Aventis Deutschland v Amgen (CFI, 16 July 2024) · Regeneron Pharmaceuticals v Amgen (CFI, 16 July 2024) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) · Dehns v Regeneron Pharmaceuticals (CFI, 22 October 2024) · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47230/2024, 22 October 20 · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47238/2024, 22 October 20
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.